Deeper Sampling and Postoperative Pain in Repeat TURBT
Yes, deeper sampling during repeat TURBT that includes the detrusor muscle is likely to result in increased postoperative pain compared to standard resection, though the overall complication profile remains acceptable and manageable.
Evidence for Increased Pain with Deeper Resection
The most recent prospective data directly addresses this concern. A 2025 multicenter study found that female sex and having stage ≥T2 bladder cancer on final pathology (which requires deeper resection) were significantly associated with greater suprapubic pain during the postoperative period 1. This suggests that the depth of resection does correlate with pain intensity.
Pain Profile After TURBT
From the same contemporary cohort 1:
- Suprapubic pain was the most prominent symptom, with patients in the highest tertile experiencing mean pain scores 5.6 times higher than those in the middle tertile
- Dysuria and penile/vaginal pain were also significant, at 2.4 times higher in the most symptomatic patients
- Most patients (79.3%) experienced hematuria
- One-third had bladder spasms and incontinence
- Nearly 25% reported constipation issues
- 10.1% required unplanned emergency room or clinic visits
Why Deeper Sampling Is Still Necessary
Despite the increased pain risk, repeat TURBT with deep sampling including detrusor muscle is strongly recommended for T1 disease 2. The clinical rationale:
- Diagnostic benefit: Detrusor muscle sampling is critical for accurate staging
- Therapeutic benefit: Residual disease rates are substantial (31-41% in various studies) 3, 4
- Prognostic benefit: Upstaging occurs in 3.3-11% of cases 3, 5
The 2016 AUA/SUO guideline explicitly states: "In a patient with T1 disease, a clinician should perform repeat transurethral resection of the primary tumor site to include muscularis propria within six weeks of the initial TURBT" 2.
Managing the Pain-Benefit Tradeoff
Patient Counseling Points:
- The procedure will likely be more uncomfortable than the initial resection
- Pain is typically manageable with standard analgesics
- Most complications are Clavien-Dindo grade I or II (mild) 6
- Overall complication rate is approximately 8.1%, with pain/spasm occurring in 3% 6
- The oncologic benefit (detecting residual disease and preventing understaging) outweighs the temporary discomfort
Risk Factors for Higher Pain:
- Female sex (significantly higher suprapubic pain) 1
- Deeper tumor stage requiring more extensive resection 1
- Prior complications from previous TURBT 6
Potential Strategies to Minimize Burden:
Recent evidence suggests that immediate second resection (additional deep biopsies during the same initial session) may be preferable to a separate restaging procedure 2-6 weeks later 4. This approach:
- Achieves 97% detrusor muscle sampling (vs. 66% with standard approach)
- Reduces residual disease at restaging (15% vs. 41%)
- Eliminates the need for a second anesthetic and recovery period
Common Pitfall
Do not skip repeat TURBT with deep sampling in T1 disease to avoid patient discomfort. The 2025 IBCG guidelines acknowledge that "clinicians should recognize the treatment burden on patients and caregivers" 7, but this applies to the overall treatment strategy, not to omitting necessary staging procedures. Inadequate initial resection and understaging are major contributors to recurrence and progression.
The temporary increase in postoperative pain is an acceptable trade-off for the critical oncologic information obtained from proper deep sampling of the detrusor muscle.